At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 263 enrolled
Drug / intervention
Bimatoprost 0.03%drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension
In Brief
A Phase 4 clinical trial evaluating Bimatoprost 0.03% for Glaucoma, Open-Angle and Ocular Hypertension. Completed, enrolled 263 participants across 1 site.
Detailed Summary
This is a study of bimatoprost as initial, replacement, or adjunctive intraocular pressure (IOP)-lowering therapy in patients with primary open angle glaucoma and ocular hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Open-Angle, Ocular Hypertension
CountriesChina
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2010
Primary CompletionJun 2011
First PostedFeb 2014
TodayJul 2026
First PostedFeb 13, 2014
Enrollment StartApr 19, 2010
Primary CompletionJun 24, 2011
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 12.4 years ago
Interventions
Bimatoprost 0.03%drug
Bimatoprost 0.03% (LUMIGAN®) 1 drop in the affected eye(s) once daily as monotherapy or adjunctive therapy for 3 months.